Applied DNA Clinical Labs has submitted a validation package to the New York State Department of Health to request ...
16h
Naveris, Inc., the leader in precision oncology diagnostics for viral-induced cancers, today announced the analytical validation of NavDx+Gyn, an important extension of the NavDx® blood test.
NEW YORK – Invivoscribe announced Thursday that its test for FLT3 mutations in patients with leukemia has achieved regulatory compliance in the UK and Switzerland.
The observational study measured how physicians changed treatment plans after seeing HER2DX results and how patients did on the new plans.
The study demonstrates that PAC-MANN-1 outperforms the widely used CA 19-9 biomarker, offering greater accuracy in detecting all stages of PDAC. The assay is particularly promising for identifying ...
The firm's next-generation pancreatic cancer test looks for five biomarkers that are indicative of early-stage disease.
The new CRISPR-Cascade assay enables highly sensitive, multiplexed detection of pathogens within minutes. Read now.
Gene Solutions, a leading biotech company in Asia, proudly announces a groundbreaking achievement in cancer early detection.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback